India: The Trickle-Down Effect Of Product Patent In India And On The Developing World

Last Updated: 12 September 2013
Most Read Contributor in India, September 2016

Article by Kailash Choudhary and Ritiraj 1

The Indian Patent Regime has been instrumental for the development of the Indian Generic drugs industry, making possible the production and availability of essential drugs at affordable prices. Prior to the WTO and TRIPS the two distinct features of the Indian Patents Act, 1970, i.e. allowing only for process patent and not product patent by virtue of Section 5 of the Indian Patents Act, 1970, are the major factors for the growth of generic industry. The then act was prepared keeping in mind the socio-econimic condition of the country and was largely based on the recommendations of a report of a Ayyangar commission.

The growth of generic pharmaceutical industry due to the favorable patent regime not only had impact in India but also well beyond its borders. India is the main supplier of essential medicines for developing countries. As per the Annual Supply Report of UNICEF, India was the largest supplier country in 2012. UNICEF procured $558 million worth of services and supplies from India2. Further as per the reports of Campaign for Access to Essential Medicines, around 67 % of medicines exports from India go to developing countries, around 75-80% of all medicines distributed by the International Dispensary Association (IDA) to developing countries are manufactured in India. In Zimbabwe, 75% of tenders for medicines for all public sector health facilities come from Indian manufacturers. The state procurement agency in Lesotho, NDSO, states it buys nearly 95% of all ARVs from India3. This is the reason why India is known as the doctor without borders. But the recent change in the Patents Act, 1970 in order to harmonize it with the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement, may leave least developing nations and the developing ones in a big trouble, who were dependent on India's generic pharmaceutical industry.

The Patents Amendment Act, 2005, introduced "Product Patent" in India. The product patent was granted for the new product for a period of twenty years. Earlier due to absence of product patent, only process patents are granted for a new process of manufacturing an already known product or for manufacturing a new product. This has helped Indian pharmaceutical industry to develop generic versions of the new medical drugs without having fear of infringement of patent. This has also helped in achieving a key-objective of policymakers in the developing world to ensure the availability of new medical treatments to save millions of lives by production of cheap generic versions of on-patent drugs. The introduction of product patents is considered as a major incentive for developing new medicines, especially for tropical diseases, not focused upon by the developed nations, it has a snowball effect on the Generic industries with only one saving clause.

The Current Situation

Earlier the Indian pharmaceutical industries by using the process of reverse engineering, various Indian pharmaceutical industries produced generic drugs on mass level of the on-patent drugs, enabling affordable access of these to under-developed and developing nations. The product patents regime means, that Indian generic drugs manufacturers can no longer manufacture drugs by reverse engineering till the time patent is in force. Due to the low per capita income the Indian people may not be able to afford the escalated costs of new entrant drugs developed by the Pharmaceutical giants. For e.g. "Shanvac", a recombinant DNA vaccine for Hepatitis B, indigenously developed by Shanta Biotech of India is being supplied to UNICEF for 50 cents per dose, whereas the same vaccine was being sold for US $ 15 per dose. Therefore, India should be either allowed to reverse engineer or should innovate in order to afford newer and better drugs.

The generic drugs are as effective as the original branded/patents drug because the same active drug molecules was used, and are a lot cheaper than the original branded drugs. The generic drugs are cheaper because the manufacturers of the same don't have to go through the process of drug development, including clinical trials, multitude of test, marketing, promotion etc. Generic drug manufacturers actually cash on the benefit of the previous marketing efforts of the patentee. Almost all drugs produced by generic manufacturers have already been on the market and are well known to patients and providers. After the change in Patent Act, same is no longer be possible, and it threatens the supply of generic drugs to the heavily dependent countries along with the domestic market.

Among Indian industries, the average investment in R&D is only 0.7 per cent which is extremely low by world standards. The lack of R&D investment is largely because of the protectionism and a non-competitive market due to the high import duties imposed on imported drugs. The number of patent applications filed by Indian institutions is very less. Some prominent Indian applicants are Council of Scientific and Industrial Research and National Institute of Pharmaceutical Education and Research (NIPER) and Indian Council of Medical Research. Drug discovery research is still finding its feet in India. Though many companies are investing like Ranbaxy, Nicholas Piramal, Cipla, CadilaPharma and Lupin, however it will at least be a decade before a critical mass is in place and results start accruing. This would mean that most of the pharmaceutical product patents would be owned by MNCs. Almost all of India's drug market consists of second-and-third generation drugs no longer subject to patent protection. This shows that product innovation has not found its ground in India, and we are involved in the production of already existing medicines for diagnosed diseases.

The major pharmaceutical companies of developed nations mainly focus on either global scale diseases or those pertinent to their areas and did not paid attention to the tropical diseases like malaria, tuberculosis etc. these areas i.e. tropical diseases are generally avoided by the developed nations as the return is not very high from the developing nations or least developed nations. This is the main reason behind the introduction of product patent that might after-all encourage research and development in the field of tropical diseases. Product patents are a crucial factor in innovation, ensuring that investor companies will have the possibility of being rewarded for the major investments needed to develop new medicines and cures. This system provides a higher degree of assurance to developers to risk the capital necessary in the research and development process.

The only valid opposition to the product patent is the price of the patented drug. For this a study of system of pricing of the medicines and the patented drugs shows us that it can be made acceptable by using Article 7 of the TRIPS Agreement, according to it "the protection and enforcement of intellectual property rights should be in a manner conducive to the socio-economic welfare of the country, and the flexibilities of the agreement".

Costing of Drugs

The march for product patent rose after declaration of $802 million as the cost incurred for drug development by the 2003 study conducted by Tufts Center for the Study of Drug Development4. Donald Light, professor of comparative health care at the University of Medicine and Dentistry of New Jersey, criticizing the study, says, that it's impossible to determine how far prices are truly rising because of increasing developmental costs, the industry keeps a tight grab on the cost and only part is disclosed at intervals and that to only economists having ties with the industry. Recognizing a trend of rising trial complexity is one thing, accurately estimating how that is affecting the cost of research and development quite another5.

The patent protects the investment, including research, development, marketing, and promotion, by giving the company the exclusive right to sell the drug for patent term. As the patent reaches the near the expiration, generic manufacturers apply to the FDA (Food and Drug Authority) in the US and in India to make and sell the generic versions. As those generic manufacturers don't have to bear the same development costs, they can sell their product at substantial discounted rates. Once the generic drugs are approved due to competition in the market, price of the drug goes down. Today, almost half of all prescriptions are filled with generic drugs and India it is required by the Government to prescribe affordable generic drugs. The US$802- million figure was based on the research-and-development costs of 68 drugs of 10 companies. The data, however, were not made available to other researchers, and drug-industry watchdogs say this lack of transparency is typical. Warburton says it is in the best interests of drug companies, who often lobby governments to loosen price regulations and increase patent protection, to overstate costs and lacking transparency makes things even fishier.

Drug companies are sometimes accused of passing these big numbers on to the media to deflect public criticism about price gouging. Another criticism of studies that produce numbers in the billion-dollar range is that large portions of those estimates aren't out-of-pocket expenses. About half of the 10-figure price tag is an estimate of the profits a drug company might have made, over the course of bringing a product to market, if it had instead invested its capital elsewhere. Calculating forgone profits is, according to Prof. Light, a reasonable way for a company to determine if it should go ahead with a project. "What is not reasonable," he says, "is to then take that estimate, which is a calculation of investment, and claim it as a cost against society6." This represents the condition of double-pricing, i.e. the company is allowed to charge for the patent the other companies buy from it, on the justification that it spent that money on developing the product; again, the company recovers that capital invested in the development of the drug by adding Maximum Allowable Post-Manufacturing Expenses to the cost of the product.

The cost estimate of successful drug development also includes the cost of research that fails to net new products. About two-thirds of true research and development costs, Light says, are incurred in phase III trials, where the odds of success are about 3 in 5. Earlier trials are relatively inexpensive, and most compounds don't even make it to the trial stage. "It is business," says Prof. Light. "It's not unlike marketing the newest version of a cell phone7."

Compulsory Licensing as a Tool to Combat Product Patents

India fought hard against product patents on medicines, however lost that battle, but did score an important victory. It got inserted in the Agreement on TRIPs, a provision whereby member countries would retain the right to issue compulsory license to domestic firms for a patented medicine if the patent holder did not provide the medicine at an affordable price8.

As compulsory licensing can be used only for drugs not available to people at affordable prices, with a company ready to manufacture it at cheap prices, it might not encourage generic industries to the extent as process patent did. Hence, using Article 7 of the TRIPS Agreement, country can make compulsory licensing flexible to provide for its domestic market and perform its responsibility of being the "pharmacy of the world". Considering the dependence of other nations on India's generic drug industry, India needs to provide sustainable and affordable access of drugs to them and its domestic market (considering their inefficiency in satisfying the market at the current rates of patented drugs). For the same, pricing of patented products has to be looked into, its anomalies removed and supported by flexible compulsory licensing.


High prices of the patented products are not the inventive for the innovation of new drugs. In order to survive in the extremely competitive market companies need to innovate or improving the existing ones. Therefore high pricing in the name of further innovation does not hold the ground.

The economic condition of the India can be taken as a standard, if India cannot afford the drugs; nearly three forth of the countries will also not as they themselves dependant on the Indian generic industry. If drugs for cure of tropical diseases like tuberculosis, polio etc. are restricted to patented drugs, the very purpose of their innovation will be defeated, which is to protect people from those diseases. The majority of the people would not be able to afford them. Further new medicines for the cure of cancer or HIV can only extend life, if available, of the prospective millions of patients. These drugs could be just chemicals stored in the containers until and unless made available to the patients.


1 IIIrd year student NLU Delhi

2 UNICEF Supply Annual Report 2012:

3 "Examples Of The Importance Of India As The "Pharmacy Of The Developing World"- Campaign for access to essential medicines ( )

4 Journal of Health Economics, March edition, 2003.

5 ibid

6 At

7 At

8 At

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.